BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 3220091)

  • 1. Pharmacokinetics of oxaprozin in women receiving conjugated estrogen.
    Scavone JM; Ochs HR; Greenblatt DJ; Matlis R
    Eur J Clin Pharmacol; 1988; 35(1):105-8. PubMed ID: 3220091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics.
    Karim A; Noveck R; McMahon FG; Smith M; Crosby S; Adams M; Wilton J
    J Clin Pharmacol; 1997 Apr; 37(4):267-78. PubMed ID: 9115051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine.
    Scavone JM; Greenblatt DJ; Matlis R; Harmatz JS
    Eur J Clin Pharmacol; 1986; 31(3):371-4. PubMed ID: 3792438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inverse nonlinear pharmacokinetics of total and protein unbound drug (oxaprozin): clinical and pharmacokinetic implications.
    Karim A
    J Clin Pharmacol; 1996 Nov; 36(11):985-97. PubMed ID: 8973987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipyrine pharmacokinetics in women receiving conjugated estrogens.
    Scavone JM; Greenblatt DJ; Blyden GT
    J Clin Pharmacol; 1988 May; 28(5):463-6. PubMed ID: 3392245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaprozin pharmacokinetics in patients with congestive heart failure.
    Ochs HR; Greenblatt DJ; Knüchel M
    Arzneimittelforschung; 1986 Dec; 36(12):1837-40. PubMed ID: 3566846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of chronic renal failure on oxaprozin multiple-dose pharmacokinetics.
    Audet PR; Knowles JA; Troy SM; Walker BR; Morrison G
    Clin Pharmacol Ther; 1988 Sep; 44(3):303-9. PubMed ID: 3416552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics of oxaprozin.
    Davies NM
    Clin Pharmacokinet; 1998 Dec; 35(6):425-36. PubMed ID: 9884815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaprozin pharmacokinetics in the elderly.
    Greenblatt DJ; Matlis R; Scavone JM; Blyden GT; Harmatz JS; Shader RI
    Br J Clin Pharmacol; 1985 Mar; 19(3):373-8. PubMed ID: 3986088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The transsynovial distribution of oxaprozin.
    Kurowski M; Thabe H
    Agents Actions; 1989 Jun; 27(3-4):458-60. PubMed ID: 2801338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Panic disorder in a patient taking oxaprozin.
    Hough DW; Sellers R; Cantilena LR
    Am J Psychiatry; 1995 Jan; 152(1):149. PubMed ID: 7802107
    [No Abstract]   [Full Text] [Related]  

  • 12. The elimination profiles of oxaprozin in equine urine and serum after a 4.8-g dose.
    Marland A; Sarkar P; Leavitt R; Lee-Ruff E; Ramnauth J
    J Anal Toxicol; 1999; 23(4):242-6. PubMed ID: 10445486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxaprozin disposition in renal disease.
    Chiang ST; Morrison G; Knowles JA; Ruelius HW; Walker BR
    Clin Pharmacol Ther; 1982 Apr; 31(4):509-15. PubMed ID: 7060332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacokinetics of oxaprozin after multiple doses].
    Suwa T; Urano H; Tsuji A
    Yakugaku Zasshi; 1987 Jun; 107(6):440-8. PubMed ID: 3681662
    [No Abstract]   [Full Text] [Related]  

  • 15. [Determination of oxaprozin in human plasma with high performance liquid chromatography (HPLC) and its application].
    Mao M; Wang L; Jiang X; Yang L
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2013 Jun; 30(3):646-50. PubMed ID: 23865335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxaprozin: a once-daily nonsteroidal anti-inflammatory drug.
    Miller LG
    Clin Pharm; 1992 Jul; 11(7):591-603. PubMed ID: 1617910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assay interaction between oxaprozin and phenytoin.
    Patel T; Radomski KM; Chandler MH
    Ann Pharmacother; 1997 Feb; 31(2):254. PubMed ID: 9034434
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of food on oxaprozin bioavailability.
    Chiang ST; Knowles JA; Hubsher JA; Ruelius HW; Walker BR
    J Clin Pharmacol; 1984; 24(8-9):381-5. PubMed ID: 6480879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaprozin: kinetic and dynamic profile in the treatment of pain.
    Kean WF
    Curr Med Res Opin; 2004 Aug; 20(8):1275-7. PubMed ID: 15324530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative irritancy of oxaprozin on the gastrointestinal tract of rats and mice: relationship to drug uptake and effects in vivo on eicosanoid metabolism.
    Rainsford KD
    Aliment Pharmacol Ther; 1988 Oct; 2(5):439-50. PubMed ID: 2979266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.